Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, single-arm, phase II study to evaluate the efficacy and
safety of lenvatinib in combination with pembrolizumab as a neoadjuvant therapy in subjects
with resectable hepatocellular carcinoma (HCC).